Edgar Filing: BELLICUM PHARMACEUTICALS, INC

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Slawin Kevin M.

2. Issuer Name and Ticker or Trading Symbol
BELLICUM PHARMACEUTICALS, INC [BLCM]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
CMO and CTO

(Last)

(First)

(Middle)

C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800

3. Date of Earliest Transaction (Month/Day/Year)
12/23/2014

(Street)

HOUSTON, TX 77030

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/23/2014		C		17,135	A	⁽¹⁾	356,370	I	By the Jordana Slawin 2012 Family Trust ⁽²⁾
Common Stock	12/23/2014		C		64,310	A	⁽³⁾	420,680	I	By the Jordana Slawin 2012 Family Trust ⁽²⁾
Common Stock	12/23/2014		C		41,801	A	⁽³⁾	462,481	I	By the Jordana Slawin 2012 Family Trust ⁽²⁾
Common Stock	12/23/2014		C		16,470	A	⁽¹⁾	310,587	I	By the Kevin Slawin 2009 Family Trust ⁽⁴⁾
Common Stock	12/23/2014		C		56,048	A	⁽³⁾	366,635	I	By the Kevin Slawin 2009 Family Trust ⁽⁴⁾
Common Stock	12/23/2014		C		36,431	A	⁽³⁾	403,066	I	By the Kevin Slawin 2009 Family Trust ⁽⁴⁾
Common Stock	12/23/2014		C		16,904	A	⁽¹⁾	21,805	I	By the 2009 Slawin Family Partnership ⁽⁵⁾
Common Stock	12/23/2014		C		65,008	A	⁽⁶⁾	86,813	I	By the 2009 Slawin Family Partnership ⁽⁵⁾
Common Stock	12/23/2014		C		15,666	A	⁽³⁾	102,479	I	By the 2009 Slawin Family Partnership ⁽⁵⁾
Common Stock	12/23/2014		C		10,182	A	⁽³⁾	112,661	I	By the 2009 Slawin Family Partnership ⁽⁵⁾
Common Stock	12/23/2014		J⁽⁷⁾		2,537	A	⁽³⁾	115,198	I	By the 2009 Slawin Family Partnership ⁽⁵⁾
Common Stock	12/23/2014		C		22,875	A	⁽³⁾	149,639	D
Common Stock	12/23/2014		C		14,868	A	⁽³⁾	164,507	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series A Convertible Preferred Stock

⁽¹⁾

12/23/2014

29,130

⁽¹⁾

Common Stock

17,135 ⁽⁸⁾

$ 0

By the Jordana Slawin 2012 Family Trust ⁽²⁾

Series A Convertible Preferred Stock

⁽¹⁾

12/23/2014

28,000

⁽¹⁾

Common Stock

16,470 ⁽⁸⁾

$ 0

By the Kevin Slawin 2009 Family Trust ⁽⁴⁾

Series A Convertible Preferred Stock

⁽¹⁾

12/23/2014

28,737

⁽¹⁾

Common Stock

16,904 ⁽⁸⁾

$ 0

By the 2009 Slawin Family Partnership ⁽⁵⁾

Series B Convertible Participating Preferred Stock

⁽⁶⁾

12/23/2014

110,514

⁽⁶⁾

Common Stock

65,008 ⁽⁸⁾

$ 0

By the 2009 Slawin Family Partnership ⁽⁵⁾

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

38,889

⁽³⁾

Common Stock

22,875 ⁽⁸⁾

$ 0

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

109,328

⁽³⁾

Common Stock

64,310 ⁽⁸⁾

$ 0

By the Jordana Slawin 2012 Family Trust ⁽²⁾

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

95,283

⁽³⁾

Common Stock

56,048 ⁽⁸⁾

$ 0

By the Kevin Slawin 2009 Family Trust ⁽⁴⁾

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

26,633

⁽³⁾

Common Stock

15,666 ⁽⁸⁾

$ 0

By the 2009 Slawin Family Partnership ⁽⁵⁾

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

25,277

⁽³⁾

Common Stock

14,868 ⁽⁸⁾

$ 0

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

71,063

⁽³⁾

Common Stock

41,801 ⁽⁸⁾

$ 0

By the Jordana Slawin 2012 Family Trust ⁽²⁾

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

61,933

⁽³⁾

Common Stock

36,431 ⁽⁸⁾

$ 0

By the Kevin Slawin 2009 Family Trust ⁽⁴⁾

Series C Convertible Preferred Stock

⁽³⁾

12/23/2014

17,311

⁽³⁾

Common Stock

10,182 ⁽⁸⁾

$ 0

By the 2009 Slawin Family Partnership ⁽⁵⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Slawin Kevin M. C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON, TX 77030	X		CMO and CTO

Signatures

/s/ Kevin M. Slawin, M.D.		12/23/2014
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Series A Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
(2)	The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
(3)	The Series C Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
(4)	The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
(5)	The Reporting Person is a managing partner of the 2009 Slawin Family Partnership that owns the reported securities. The Reporting Person has the dispositive power and control over the securities held by such partnership. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
(6)	The Series B Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
(7)	On December 4, 2014, the Board of Directors of the Issuer declared a dividend payable to all holders of records of the Series B Convertible Participating Preferred Stock of the Issuer on December 16, 2014, payable in the form of cash or in shares of Common Stock of the Issuer, at the option of each holder. The dividends occurred in connection with the closing of the Issuer's public offering. The Reporting Person elected to receive the shares of Common Stock.
(8)	Reflects 1.7-for-1 reverse stock split which became effective on December 5, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.